Cargando…

Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database

OBJECTIVE: To assess the health care costs and utilization in patients with hereditary hemorrhagic telangiectasia (HHT) in the United States. PATIENTS AND METHODS: Retrospective analysis of patients with HHT diagnosed between 2007 and 2017 was performed using deidentified administrative claims data...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan Albitar, Hasan Ahmad, Van Houten, Holly, Sangaralingham, Lindsey R., Knoedler, Meghan, Almodallal, Yahya, Alkurashi, Adham K., De Moraes, Alice Gallo, Cajigas, Hector, DuBrock, Hillary, Warad, Deepti, Demirel, Nadir, Krowka, Michael, Brinjikji, Waleed, Iyer, Vivek N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930864/
https://www.ncbi.nlm.nih.gov/pubmed/33718784
http://dx.doi.org/10.1016/j.mayocpiqo.2020.08.010
_version_ 1783660171628642304
author Hasan Albitar, Hasan Ahmad
Van Houten, Holly
Sangaralingham, Lindsey R.
Knoedler, Meghan
Almodallal, Yahya
Alkurashi, Adham K.
De Moraes, Alice Gallo
Cajigas, Hector
DuBrock, Hillary
Warad, Deepti
Demirel, Nadir
Krowka, Michael
Brinjikji, Waleed
Iyer, Vivek N.
author_facet Hasan Albitar, Hasan Ahmad
Van Houten, Holly
Sangaralingham, Lindsey R.
Knoedler, Meghan
Almodallal, Yahya
Alkurashi, Adham K.
De Moraes, Alice Gallo
Cajigas, Hector
DuBrock, Hillary
Warad, Deepti
Demirel, Nadir
Krowka, Michael
Brinjikji, Waleed
Iyer, Vivek N.
author_sort Hasan Albitar, Hasan Ahmad
collection PubMed
description OBJECTIVE: To assess the health care costs and utilization in patients with hereditary hemorrhagic telangiectasia (HHT) in the United States. PATIENTS AND METHODS: Retrospective analysis of patients with HHT diagnosed between 2007 and 2017 was performed using deidentified administrative claims data from the OptumLabs Data Warehouse. Adult patients with new (incident) diagnosis of HHT between January 1, 2007, and December 31, 2017, were included. Comparisons were made using the Wilcoxon rank sum test. RESULTS: Three thousand nine hundred seventy-seven patients with a first diagnosis of HHT between 2007 and 2017 were identified, of which 3590 were matched 1:1 to non-HHT patients with similar baseline characteristics and comorbidities. These 3590 patients with HHT were 63.1% female and 83.9% white with a mean age of 51.1 ± 18.5 years, and a mean follow-up period of 3.2 ± 2.2 years (range, 1.0-11.7 years). Compared with the control group, the cumulative 5-year median total health care cost for patients with HHT was 41.4% higher ($21,118 vs $14,929; P < .001) in those with private commercial insurance and 31.7% higher ($35,462 vs $26,925; P < .001) in those with Medicare Advantage coverage. The median annual health care costs were significantly higher in patients with HHT with commercial insurance and Medicare Advantage in the first year after diagnosis ($4,333 vs $1,804; P < .001), and ($7,322 vs $5,245; P < .001), respectively, and remained higher throughout the duration of follow-up. Further analysis showed that outpatient clinic visits, hospital admission, imaging rates, invasive procedures, iron infusions, and blood transfusions were all significantly higher in the HHT group. CONCLUSION: Patients with HHT have significantly higher health care costs compared with a matched control group. A better understanding of the reasons underlying these cost differences will provide opportunities for patients, providers, and other stakeholders to better manage this rare condition.
format Online
Article
Text
id pubmed-7930864
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79308642021-03-12 Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database Hasan Albitar, Hasan Ahmad Van Houten, Holly Sangaralingham, Lindsey R. Knoedler, Meghan Almodallal, Yahya Alkurashi, Adham K. De Moraes, Alice Gallo Cajigas, Hector DuBrock, Hillary Warad, Deepti Demirel, Nadir Krowka, Michael Brinjikji, Waleed Iyer, Vivek N. Mayo Clin Proc Innov Qual Outcomes Original Article OBJECTIVE: To assess the health care costs and utilization in patients with hereditary hemorrhagic telangiectasia (HHT) in the United States. PATIENTS AND METHODS: Retrospective analysis of patients with HHT diagnosed between 2007 and 2017 was performed using deidentified administrative claims data from the OptumLabs Data Warehouse. Adult patients with new (incident) diagnosis of HHT between January 1, 2007, and December 31, 2017, were included. Comparisons were made using the Wilcoxon rank sum test. RESULTS: Three thousand nine hundred seventy-seven patients with a first diagnosis of HHT between 2007 and 2017 were identified, of which 3590 were matched 1:1 to non-HHT patients with similar baseline characteristics and comorbidities. These 3590 patients with HHT were 63.1% female and 83.9% white with a mean age of 51.1 ± 18.5 years, and a mean follow-up period of 3.2 ± 2.2 years (range, 1.0-11.7 years). Compared with the control group, the cumulative 5-year median total health care cost for patients with HHT was 41.4% higher ($21,118 vs $14,929; P < .001) in those with private commercial insurance and 31.7% higher ($35,462 vs $26,925; P < .001) in those with Medicare Advantage coverage. The median annual health care costs were significantly higher in patients with HHT with commercial insurance and Medicare Advantage in the first year after diagnosis ($4,333 vs $1,804; P < .001), and ($7,322 vs $5,245; P < .001), respectively, and remained higher throughout the duration of follow-up. Further analysis showed that outpatient clinic visits, hospital admission, imaging rates, invasive procedures, iron infusions, and blood transfusions were all significantly higher in the HHT group. CONCLUSION: Patients with HHT have significantly higher health care costs compared with a matched control group. A better understanding of the reasons underlying these cost differences will provide opportunities for patients, providers, and other stakeholders to better manage this rare condition. Elsevier 2020-11-20 /pmc/articles/PMC7930864/ /pubmed/33718784 http://dx.doi.org/10.1016/j.mayocpiqo.2020.08.010 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Hasan Albitar, Hasan Ahmad
Van Houten, Holly
Sangaralingham, Lindsey R.
Knoedler, Meghan
Almodallal, Yahya
Alkurashi, Adham K.
De Moraes, Alice Gallo
Cajigas, Hector
DuBrock, Hillary
Warad, Deepti
Demirel, Nadir
Krowka, Michael
Brinjikji, Waleed
Iyer, Vivek N.
Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title_full Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title_fullStr Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title_full_unstemmed Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title_short Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database
title_sort healthcare utilization and costs associated with hereditary hemorrhagic telangiectasia patients in a large us claims database
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930864/
https://www.ncbi.nlm.nih.gov/pubmed/33718784
http://dx.doi.org/10.1016/j.mayocpiqo.2020.08.010
work_keys_str_mv AT hasanalbitarhasanahmad healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT vanhoutenholly healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT sangaralinghamlindseyr healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT knoedlermeghan healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT almodallalyahya healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT alkurashiadhamk healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT demoraesalicegallo healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT cajigashector healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT dubrockhillary healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT waraddeepti healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT demirelnadir healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT krowkamichael healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT brinjikjiwaleed healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase
AT iyervivekn healthcareutilizationandcostsassociatedwithhereditaryhemorrhagictelangiectasiapatientsinalargeusclaimsdatabase